News BioNTech flips its cancer bispecific to BMS for a big profit Bristol Myers Squibb is spending big to avoid being left behind in the race to develop a much-touted class of bispecific antibodies for cancer.
Market Access A year of major M&A ahead? The previous few years have seen a slowdown in M&A across the industry, as companies take a cautious approach to expansion.
Sales & Marketing BMS’ Catherine Owen on pharma commercialisation: the pharmap... Episode 42 of the pharmaphorum podcast heard from Catherine Owen, who’s senior vice president of major markets at Bristol Myers Squibb, about the future of pharma commercialisation and comm
Sales & Marketing Deep Dive: Communications and Commercialisation The COVID-19 pandemic kickstarted a period of profound change in how the pharmaceutical industry approaches both communications and commercialisation.
Views & Analysis Have a chat to help others through loneliness Looking back over the past 18 months, the Joni Mitchell lyric ‘you don’t know what you’ve got til it’s gone’ comes to mind.
News Most pharmas not ready for AI in customer engagement Pharma wants to use AI for digital engagement with healthcare professionals and patients, but most feel unprepared to forge ahead, says survey.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face